Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Debt: 2019-2025

  • China SXT Pharmaceuticals' Non-Current Debt fell 1.63% to $98,126 in Q3 2025 from the same period last year, while for Sep 2025 it was $98,126, marking a year-over-year decrease of 1.63%. This contributed to the annual value of $96,264 for FY2025, which is 17.81% down from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Non-Current Debt is $98,126, which was up 1.93% from $96,264 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Non-Current Debt registered a high of $117,862 during Q1 2023, and its lowest value of $6,292 during Q1 2021.
  • Its 3-year average for Non-Current Debt is $101,894, with a median of $98,938 in 2024.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Non-Current Debt plummeted by 82.77% in 2021, and later climbed by 21.29% in 2024.
  • Over the past 4 years, China SXT Pharmaceuticals' Non-Current Debt (Quarterly) stood at $6,292 in 2021, then reached $82,237 in 2023, then climbed by 21.29% to $99,749 in 2024, then decreased by 1.63% to $98,126 in 2025.
  • Its last three reported values are $98,126 in Q3 2025, $96,264 for Q1 2025, and $99,749 during Q3 2024.